1. Home
  2. DCTH vs PANL Comparison

DCTH vs PANL Comparison

Compare DCTH & PANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DCTH
  • PANL
  • Stock Information
  • Founded
  • DCTH 1988
  • PANL 1996
  • Country
  • DCTH United States
  • PANL United States
  • Employees
  • DCTH 76
  • PANL N/A
  • Industry
  • DCTH Medical/Dental Instruments
  • PANL Marine Transportation
  • Sector
  • DCTH Health Care
  • PANL Consumer Discretionary
  • Exchange
  • DCTH Nasdaq
  • PANL Nasdaq
  • Market Cap
  • DCTH 426.3M
  • PANL 287.4M
  • IPO Year
  • DCTH N/A
  • PANL N/A
  • Fundamental
  • Price
  • DCTH $11.52
  • PANL $5.22
  • Analyst Decision
  • DCTH Strong Buy
  • PANL
  • Analyst Count
  • DCTH 4
  • PANL 0
  • Target Price
  • DCTH $24.00
  • PANL N/A
  • AVG Volume (30 Days)
  • DCTH 850.4K
  • PANL 260.9K
  • Earning Date
  • DCTH 08-04-2025
  • PANL 08-07-2025
  • Dividend Yield
  • DCTH N/A
  • PANL 3.82%
  • EPS Growth
  • DCTH N/A
  • PANL N/A
  • EPS
  • DCTH N/A
  • PANL 0.30
  • Revenue
  • DCTH $53,850,000.00
  • PANL $554,589,579.00
  • Revenue This Year
  • DCTH $155.42
  • PANL $4.72
  • Revenue Next Year
  • DCTH $37.93
  • PANL $16.57
  • P/E Ratio
  • DCTH N/A
  • PANL $17.20
  • Revenue Growth
  • DCTH 1068.87
  • PANL 13.11
  • 52 Week Low
  • DCTH $7.17
  • PANL $3.93
  • 52 Week High
  • DCTH $18.23
  • PANL $7.75
  • Technical
  • Relative Strength Index (RSI)
  • DCTH 32.83
  • PANL 64.44
  • Support Level
  • DCTH $12.11
  • PANL $5.00
  • Resistance Level
  • DCTH $14.15
  • PANL $5.28
  • Average True Range (ATR)
  • DCTH 0.57
  • PANL 0.20
  • MACD
  • DCTH -0.16
  • PANL 0.02
  • Stochastic Oscillator
  • DCTH 9.67
  • PANL 92.09

About DCTH Delcath Systems Inc.

Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.

About PANL Pangaea Logistics Solutions Ltd.

Pangaea Logistics Solutions Ltd and its subsidiaries provide seaborne drybulk logistics and transportation services. It transports various drybulk cargoes including grains, coal, iron, ore, pig, iron, hot briquetted iron, bauxite, alumina, cement clinker, dolomite, and limestone. The company provides ocean transportation services to clients utilizing an ocean-going fleet of motor vessels in the Handymax, Supramax, Ultramax, Panamax, and Post-Panamax segments. Its services include cargo loading, cargo discharge, vessel chartering, voyage planning, and technical vessel management. The company derives all of its revenues from contracts of affreightment, voyage charters and time charters. Geographically, it derives key revenue from the United States, followed by Canada, Germany, and others.

Share on Social Networks: